17% of Danish Cancer Patients Reported Peripheral Neuropathy, Higher in Cannabis Users
Among nearly 2,840 Danish cancer outpatients, 17% had significant peripheral neuropathy symptoms, and cannabis users were nearly twice as likely to report a high symptom burden.
Quick Facts
What This Study Found
Overall neuropathy prevalence was 17%, ranging from 6% to 33% across cancer types. Cannabis users had significantly higher neuropathy symptom scores (29% vs 15%, p<0.05). Patients with high neuropathy scores had substantially worse quality of life across all measures.
Key Numbers
2,839 patients surveyed (83% response rate). Overall neuropathy prevalence: 17%. Cannabis users with high score: 29% vs 15% non-users. Quality of life difference: -18.66 points on C30 SumScore (95% CI -20.31 to -17.02). Higher rates in females (19% vs 14%), smokers (21% vs 15%), patients living alone (21% vs 15%).
How They Did This
Cross-sectional survey administered to all adult outpatients at three Danish oncology departments. Used the EORTC-CIPN20 for neuropathy assessment and EORTC-QLQ-C30 for quality of life. A high symptom score was defined as CIPN20 summary score of 30 or above. Response rate: 83% (2,839 patients).
Why This Research Matters
This is one of the largest surveys of neuropathy in a general oncology population. The finding that cannabis users had higher neuropathy scores is noteworthy, though it could reflect cannabis use for symptom management rather than cannabis causing neuropathy.
The Bigger Picture
The association between cannabis use and higher neuropathy scores raises an important chicken-or-egg question. Patients with worse symptoms may turn to cannabis for relief, rather than cannabis worsening their condition. This distinction matters for clinical guidance.
What This Study Doesn't Tell Us
Cross-sectional design cannot determine whether cannabis use preceded or followed neuropathy symptoms. The study did not capture cannabis dose, frequency, or reason for use. Self-reported symptoms may differ from clinical assessment.
Questions This Raises
- ?Are cancer patients using cannabis because of neuropathy symptoms, or does cannabis worsen neuropathy?
- ?Would prospective tracking of cannabis use alongside neuropathy development clarify the direction of this association?
Trust & Context
- Key Stat:
- 29% of cannabis users vs 15% of non-users had high neuropathy scores
- Evidence Grade:
- Moderate: large cross-sectional survey with 83% response rate across three centers, though causal direction cannot be determined.
- Study Age:
- Published in 2022.
- Original Title:
- The prevalence, distribution and impact of peripheral neuropathy among Danish patients with cancer - a population-based cross-sectional study.
- Published In:
- Acta oncologica (Stockholm, Sweden), 61(3), 363-370 (2022)
- Authors:
- Nielsen, Sebastian Werngreen, Eckhoff, Lise, Ruhlmann, Christina Halgaard Bruvik, Herrstedt, Jørn, Dalton, Susanne Oksbjerg
- Database ID:
- RTHC-04103
Evidence Hierarchy
A snapshot of a population at one point in time.
What do these levels mean? →Frequently Asked Questions
Does cannabis cause neuropathy in cancer patients?
This study found an association but cannot determine causation. Patients with worse neuropathy may be more likely to try cannabis for symptom relief, creating a reverse-causation scenario.
How common is neuropathy across different cancer types?
Prevalence ranged from 6% to 33% depending on cancer diagnosis, reflecting differences in treatment regimens. The 17% overall figure provides a useful benchmark for general oncology populations.
Read More on RethinkTHC
- CBD-oil-quality-guide
- anxiety-medication-after-quitting-weed
- cannabis-chemotherapy-nausea
- cannabis-chronic-pain-research
- cannabis-epilepsy-CBD-Epidiolex
- cbd-anxiety-research-evidence
- cbd-for-weed-withdrawal
- cbd-vs-thc-difference
- medical-benefits-of-cannabis
- quitting-weed-before-surgery
- quitting-weed-medication-interactions
- quitting-weed-pregnancy
- quitting-weed-pregnant
- seniors-older-adults-cannabis-risks-medications
- weed-breastfeeding-THC-breast-milk
Cite This Study
https://rethinkthc.com/research/RTHC-04103APA
Nielsen, Sebastian Werngreen; Eckhoff, Lise; Ruhlmann, Christina Halgaard Bruvik; Herrstedt, Jørn; Dalton, Susanne Oksbjerg. (2022). The prevalence, distribution and impact of peripheral neuropathy among Danish patients with cancer - a population-based cross-sectional study.. Acta oncologica (Stockholm, Sweden), 61(3), 363-370. https://doi.org/10.1080/0284186X.2021.2007283
MLA
Nielsen, Sebastian Werngreen, et al. "The prevalence, distribution and impact of peripheral neuropathy among Danish patients with cancer - a population-based cross-sectional study.." Acta oncologica (Stockholm, 2022. https://doi.org/10.1080/0284186X.2021.2007283
RethinkTHC
RethinkTHC Research Database. "The prevalence, distribution and impact of peripheral neurop..." RTHC-04103. Retrieved from https://rethinkthc.com/research/nielsen-2022-the-prevalence-distribution-and
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.